skip to Main Content

Abstract and late breaker abstract submission for ILC 2017 is closed

Submit your late-breaking abstracts

There is a €100.00 non-refundable fee (VAT included) for submitting a late-breaker abstract.

The abstract submission fee is a non-refundable processing fee, and not based on approval of your abstract submission or attendance.

The only method of payment accepted for abstract submission fees is by credit card: Visa, EuroCard, MasterCard or American Express.

Do not withdraw a paid abstract submission. If edits are needed, submissions can be edited at any time after submission and prior to the abstract submission deadline. Simply log in on the abstract submission platform and edit your abstract. Refunds will not be issued for abstracts that are withdrawn and resubmitted.

Regular abstract submission fee

Regular Abstract submission

This year, a handling fee of €50.00 has been charged for every regular abstract submission.

If your abstract is accepted, EASL will take care of the following;

  • Free printing of your paper poster
  • Free delivery to the Amsterdam RAI venue
  • Free hanging and display of abstract in the poster board area

All you need to do is arrive on time on the day of your presentation – we take care of the rest!

Submission timeline

11 October 2016Abstract submission opens
22 November 2016 (23:59 CET)*Regular abstract submission deadline
25 January 2017Abstract notification to authors
08 February 2017Final day to withdraw accepted abstracts and/or to request modifications of titles and author lists
13 February 2017Late breaker submission opens**
22 February 2017 (midnight CET)*Late breaker submission ends
09 March 2017Late breaker abstract notification

*No abstracts will be accepted after the stated submission deadline.
**There is an EUR 100 non-refundable fee (VAT included) for submitting a late breaker abstract.


If you have questions regarding abstracts or need assistance, please contact the abstract team at

Abstract hotline: +41 (0)22 807 29 71 (CET office hours)

After having submitted your abstract, you will receive a confirmation by e-mail with your abstract reference number.

If you do not receive a confirmation e-mail please contact the abstract team

Should you wish to make corrections to an already submitted abstract, or if you wish to submit other abstracts later, you may use your personal access codes. Corrections to regular abstracts can only be made up to the submission deadline: 22 November 2016. Corrections to late-breaker abstracts can only be made up to the late-breaker submission deadline: 22 February 2017

If an abstract is accepted, the person designated as the presenting author must attend the congress to present the data in person. Acceptance of the abstract implies payment of the registration fee by the presenting author.

Abstract submission guidelines

Get ready for abstract submission, download this checklist!

Abstracts may only be submitted via Internet. Abstracts submitted by fax or email will not be accepted.

Travel bursaries are available for young investigators.

All abstracts must be submitted and presented in English. Please use UK English spelling and have your abstract proofread for grammar and syntax.

Abstracts that have previously been presented in non-EASL International Gastroenterology/Hepatology meetings will NOT be accepted. Please ensure that your abstract has never been presented before. If this rule is not respected, the abstract will be rejected, and will not be considered.

Exception: Any abstract submitted for presentation at any 2016-2017 EASL event (monothematic or special conferences) and EASL HCC Summit 2017 may also be submitted and will be considered for presentation at The International Liver Congress™ 2017.
Please note that acceptance of the abstract at an EASL event does not automatically imply acceptance at the ILC.

During the online abstract submission process you will be guided through the different steps enabling you to successfully submit your work. The structure of the abstract will be defined as follows;

Abstract topic: Please choose from the abstract categories available. Carefully select the adequate topic for your abstract submission. Misplaced abstracts may be rejected. Abstracts relating to the same study should not be split and submitted in the same topic category.

Title: The title of your abstract should be precise and explicit. The number of characters in your title should be between 50 and 250 maximum.

Authors: Please list all authors with their affiliations (institution, city and country). Email addresses can be indicated, in which case the co-author will be notified of the abstract submission.

Authors’ disclosures: All authors must disclose their conflict of interests. If your research has been granted any commercial or institutional support, you will be asked to disclose this during the submission process.

Authorship: Credit for authorship requires substantial contributions to the conception and design; or the acquisition, analysis, or interpretation of the data, final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.

Abstract body: Abstracts should be between 500 and 2,500 characters including spaces (excluding title and authors). Do not use abbreviations, footnotes or references in the abstract.

You should structure your abstract using the following headings:

  • Background and aims
  • Methods
  • Results
  • Conclusions: avoid evasive statements like “the findings will be discussed”
  • Figure: One image can be submitted. It should be in JPG/BMP format, maximum width 9cm, and resolution up to 150dpi. Please note that these may be resized to fit in the final printed material.
  • Please check the figure quality in the abstract preview before submitting your abstract. EASL reserves the right to remove any figure that is not of sufficient quality for publication.

Drugs and chemicals: Generic names of drugs and chemicals should be provided. If trademarks are mentioned, the manufacturer’s name and city should also be given. All funding sources supporting the work, either public or private, especially those from pharmaceutical companies, must be provided.

  • Acute liver failure: Clinical and experimental
  • Alcoholic liver disease
  • Autoimmune and chronic cholestatic liver disease:
    1. Clinical aspects
    2. Experimental and pathophysiology
  • Cirrhosis and its complications:
    1. Clinical aspects
    2. Experimental and pathophysiology
  • Drug induced liver injury
  • EU and Public Health
  • Fatty liver disease:
    1. Clinical
    2. Experimental and pathophysiology
  • Genetic and paediatric liver diseases
  • Liver transplantation / surgery:
    1. Clinical aspects
    2. Experimental and pathophysiology
  • Liver tumours:
    1. Clinical (epidemiology, diagnosis) and management
    2. Experimental and pathophysiology
  • Molecular and cellular biology:
    1. Cell cycle control / apoptosis
    2. HSCs and fibrosis
  • Non-invasive assessment of liver disease
  • Viral hepatitis:
    1. Hepatitis A, B, D E – Clinical (except therapy)
    2. Hepatitis B and D – Clinical (therapy, new compounds, resistance)
    3. Hepatitis B and D – Experimental and pathophysiology
    4. Hepatitis C – Clinical (except therapy)
    5. Hepatitis C – Clinical (therapy)
    6. Hepatitis C – Experimental (virology)
    7. Immunological aspects


By submitting an abstract to the ILC 2017 you agree with the statement below:

I hereby assign the copyrights to the European Association for the Study of the Liver (EASL) in the abstract (government authors not electing to transfer, agree to assign an exclusive publishing and distribution license) and any supplementary tables, illustrations or other information submitted therewith, that are intended for publication as part of the abstract, in all forms and media (whether now known or hereafter developed), throughout the world, in all languages, for the full term of copyright, effective when and if the article is accepted for publication. This transfer includes the right to provide the abstract in electronic and online forms and systems.

Abstract presentation, modification and withdrawals

The presenting author of an accepted abstract must attend and register for the congress. All accepted abstracts will be published in a supplement of the Journal of Hepatology.

Additions or removal of author names will be permitted until 8 February 2017. After this date no further changes in the abstract will be possible. Any changes in the abstract title or body will not be possible after the submission deadline 22 November 2016.

After acceptance of the abstract, requests for withdrawal of an abstract must be received in writing to by 8 February 2017 to avoid publication in the Journal of Hepatology supplement and final programme. Any withdrawal requested after that date will not be considered and the abstract will be published in the Journal of Hepatology supplement.

For late breaker abstracts,

changes in the abstract title or body will not be possible after the submission deadline 22 February 2017.  Additions or removal of author names will be permitted until 15 March 2017. After acceptance of the late-breaker abstract, requests for withdrawal of an abstract must be received in writing to by 15 March 2017 to avoid publication in the Journal of Hepatology supplement and final programme. Any withdrawal requested after that date will not be considered and the abstract will be published in the Journal of Hepatology supplement.

Embargo policy

A large quantity of abstracts, including some late-breaker abstracts, will be published on the ILC 2017 website and ILC app ahead of the congress showing abstract title, author’s names and abstract data.

A smaller quantity of abstracts will be retained and presented during the official EASL Press Office activities and/or in official EASL Press Office materials. These abstracts are under embargo and embargoed abstract titles, authors and institute names will be made available on the congress website, but related data will only be released during the congress.
Read the ILC 2017 embargo policy.